ライフサイエンスコーパス: ABI

1 ABI and CVD risk factors were measured at Visit 2 (1990

2 ABI values from each subject's earliest vascular laborat

3 ABI-007 demonstrated significantly higher response rates

4 ABI-1, a downstream target of Abl non-receptor tyrosine

5 ABI-H0731 was rapidly absorbed and exhibited a plasma ha

6 ABI-III analogues maintain their mechanisms of action by

7 ABI-III compounds are highly potent against a panel of m

8 ell's C statistic (0.74 vs. 0.76; p = 0.04); ABI, hsCRP levels, and FH produced no improvement in Har

9 The proportion of patients with > or =1 ABI value < or =0.9, indicating obstructed lower limb ar

10 t and isolated Abelson-interactor protein-1 (ABI-1).

11 0B interacts with Abl-interacting protein-1 (ABI-1)/Abi1, a component of the WAVE complex, to organiz

12 In part 1, ABI-H0731 reached maximum plasma concentrations (T(max))

13 p140/PIR121, GEX-3/NAP1/HEM2/KETTE, or ABI-1/ABI, the three other components of the C. elegans WAVE/S

14 From 1995 to 1998, ABI was measured in 1,097 men and 1,189 women (mean age

15 (RR: 1.9) at 6 years, independent of Visit 2 ABI and other risk factors.

16 e cases, low (0.70 < or = ABI <0.90) Visit 2 ABIs were associated with significantly elevated all-cau

17 Both a low (<1.00) and a high (>/=1.40) ABI were associated with incident CVD events.

18 w normal ABI (1.00 to 1.09), and normal ABI (ABI 1.10 to 1.30).

19 han traditional risk factors and an abnormal ABI.

20 ound to be reduced in subjects with abnormal ABI, manifesting in prolonged recovery during the early

21 Abnormal ABIs, both low and high, are associated with elevated ca

22 The implementation of an alternative ABI method and use of the brachial difference identifies

23 Of those remaining, an alternative ABI method using the lower of the 2 ankle pressures assi

24 An ABI 1.00 to 1.30 was considered normal, PAD was defined

25 An ABI dependence was found in both PHF (p = 0.04) and TTP

26 -exercise ABI </=0.90, and PCA defined as an ABI >/=1.4 and/or an ankle systolic blood pressure >255

27 brachial index (ABI) and PAD (defined as an ABI < 0.90) have not been conducted in Hispanics/Latinos

28 PAD was defined as an ABI less than 0.90.

29 A total of 296 subjects had an ABI >or=1.40 in at least 1 leg, and 4,420 had an ABI bet

30 >or=1.40 in at least 1 leg, and 4,420 had an ABI between 0.90 and 1.40.

31 from a community health registry, and had an ABI screening test.

32 tion with 157 nm light was implemented in an ABI model 4700 matrix-assisted laser desorption ionizati

33 rachial index (ABI) at rest and typically an ABI </= 0.90 is used to define LE-PAD.

34 DNA was sequenced by the Genetic Analyzers ABI Prism 310 (Perkin Elmer) or 3500 (Applied Biosystems

35 stem confirmed the interaction of MIG-10 and ABI-1 and showed that it requires the SH3 domain of ABI-

36 These results suggest that MIG-10 and ABI-1 interact physically to promote cell migration and

37 our results suggest that MIG-10, UNC-53, and ABI-1 act sequentially to mediate excretory cell process

38 t PAD cases were identified for ABI <0.9 and ABI >1.4, respectively.

39 Although only 12% of the ABA- and ABI-dependent transcriptional targets were induced by bo

40 e investigate the molecular basis of ABI and ABI-attenuation through the lens of NMR and coupled ther

41 ms of aggregation-based inhibition (ABI) and ABI-attenuation by additives, such as Triton X-100 (TX)

42 We obtained CCT and ABI measurements in 588 RA patients.

43 on the SmartCycler II, ABI 7500 Fast DX, and ABI QuantStudio DX instruments compared to CCNA were 90.

44 ears of age and measured kidney function and ABI.

45 d based on our previously reported ABI-I and ABI-II analogues.

46 ation in men and with common carotid IMT and ABI in women (all P<0.05) after adjustment for model 1 v

47 0.34) and -0.22 (SE 0.35), respectively] and ABI after exercise [-0.29 (SE 0.34) and -0.30 (0.35), re

48 significant changes in iCIMT, CAC score, and ABI were not observed.

49 ata from the Roche 454, Illumina/Solexa, and ABI SOLiD platforms typically present shorter read lengt

50 -Bar virus (EBV) PCR assays with the WHO and ABI standards as examples.

51 s pedis artery or posterior tibial artery) ("ABI-LO"), 2) with the highest ankle pressure ("ABI-HI"),

52 ment-emergent adverse events was observed at ABI-H0731 doses up to 300 mg in individuals with chronic

53 TX attenuates ABI by converting inhibitory, protein-binding aggregates

54 The mean baseline ABI in all patients was 0.71, 76.6% of the patients had

55 ared with persons who have a normal baseline ABI.

56 ed with ABI change independently of baseline ABI and cardiovascular disease risk factors.

57 ycler 480 system and the Applied Biosystems (ABI) 7500 real-time PCR system.

58 HR: 3.22 (95% CI: 1.43 to 7.21); borderline ABI, HR: 3.07 (95% CI: 1.21 to 7.84); and low normal ABI

59 women (2.85 (definite PAD), 1.27 (borderline ABI), 1.11 (low-normal ABI), 1.00 (normal ABI; referent)

60 d men (3.26 (definite PAD), 1.72 (borderline ABI), 1.14 (low-normal ABI), 1.00 (normal ABI; referent)

61 69), mild PAD (ABI 0.70 to 0.89), borderline ABI (0.90 to 0.99), low normal ABI (1.00 to 1.09), and n

62 At 5-year follow-up, persons with borderline ABI values have a higher incidence of mobility loss and

63 transcriptional targets were induced by both ABI factors in 11 day old plants, 40% of those normally

64 correlate with disease state as measured by ABI and demonstrate preserved microvascular flow reserve

65 rior tibial arteries, the authors calculated ABI in 3 ways: 1) with the lowest ankle pressure (dorsal

66 In the excretory canal, ABI-1 is thought to act downstream of UNC-53/NAV2, linki

67 , but homology to a previously characterized ABI Five Binding Protein (AFP).

68 the tonotopic frequency gradients of the CN, ABIs improve speech understanding to varying degrees.

69 usting for age, gender, race, comorbidities, ABI, and other confounders, participants in the poorest

70 Continuous ABI and PAD (ABI </=0.9) phenotypes adjusted for age and

71 Analyses were performed on normalized crude ABI and on normalized residuals from multiple linear reg

72 Current ABI protocols might need to be evaluated.

73 Patients with decreasing ABI may be candidates for more intensive cardiovascular

74 on or stenoses, peripheral arterial disease (ABI <1.0), symptomatic cardiac disease, unrelated causes

75 DCN) contributes to patients' hearing during ABI stimulation.

76 ectively, for incident PAD defined as either ABI <0.9 or ABI >1.4.

77 The authors sought to estimate ABI heritability in a community-based sample.

78 AD was defined as a resting or post-exercise ABI </=0.90, and PCA defined as an ABI >/=1.4 and/or an

79 5% confidence interval (CI): 0.32, 1.01) for ABI <0.9 and 2.24 (95% CI: 1.01, 4.32) for ABI >1.4.

80 r ABI <0.9 and 2.24 (95% CI: 1.01, 4.32) for ABI >1.4.

81 lts suggest the importance of accounting for ABI values of all 4 leg arteries in clinical practice an

82 No other SNP associations for ABI or PAD achieved genome-wide significance.

83 Mutations in genes for ABI domain proteins, designated spdA, spdB and spdC (sur

84 We also performed GWAS for ABI stratified by Hispanic/Latino ethnic subgroups: Cent

85 d 206 incident PAD cases were identified for ABI <0.9 and ABI >1.4, respectively.

86 We noted a similar pattern for ABI values >1.3, indicative of arterial incompressibilit

87 ture, has been considered a logic target for ABI stimulation, it is not yet clear how the dorsal coch

88 d interleukin-6 at baseline had the greatest ABI decline.

89 duals assigned to the traditional-PAD group (ABI <0.90) with the traditional ABI method.

90 High ABI is associated with greater LV mass; an association t

91 High ABI might lead to greater LV mass through nonatheroscler

92 1.00 (normal ABI; referent), and 1.43 (high ABI); p for trend = 0.0002).

93 1.00 (normal ABI; referent), and 0.78 (high ABI); p for trend = 0.0002) and men (3.26 (definite PAD)

94 001) for a low and 1.85 (p=0.050) for a high ABI after adjustment for both traditional and newer biom

95 Individuals with a high ABI have higher odds for foot ulcers and neuropathy, as

96 In humans, a high ABI indicates stiff peripheral arteries and is associate

97 In this study, both a low and a high ABI were associated with elevated CVD risk in persons fr

98 A high ABI, a marker of lower extremity arterial stiffness, is

99 rence were positively associated with a high ABI, and smoking and dyslipidemia were inversely associa

100 n, 0.4), 6% had a low ABI, and 5% had a high ABI.

101 ad CKD, 13% had a low ABI, and 3% had a high ABI.

102 idemia were inversely associated with a high ABI.

103 nterval [CI]: 1.6 to 2.5; p <0.001) and high ABI (RR: 1.6; 95% CI: 1.0 to 2.3; p = 0.03).

104 The association between CKD and high ABI is unknown.

105 1) and a 1.4-fold greater prevalence of high ABI (95% CI: 1.0, 1.9; P = 0.03) in models adjusted for

106 84 to 3.33), whereas the association of high ABI was minimally altered (6.01 g/m(2) higher, 95% confi

107 % confidence interval: 0.65 to 4.75) or high ABI (6.84 g/m(2) higher, 95% confidence interval: 3.2 to

108 ccounting for multiple comparisons, the high ABI group had significantly higher odds for foot ulcers

109 usting for patients with other CVD, the high ABI group scored 2.0 points lower on the physical compon

110 Whether high ABI is associated with LV mass in humans and whether thi

111 ver, the association of phosphorus with high ABI differed by chronic kidney disease (CKD) status (in

112 th low ABI and are also associated with high ABI in persons with CKD.

113 han 20 decreased across progressively higher ABI categories in both women (2.85 (definite PAD), 1.27

114 We have recently identified ABI family, member 3 (NESH) binding protein (Abi3bp) as

115 ity of the Lyra assay on the SmartCycler II, ABI 7500 Fast DX, and ABI QuantStudio DX instruments com

116 ity of the Lyra assay on the SmartCycler II, ABI 7500, and QuantStudio instruments were 82.1% and 96.

117 viously reported 2-aryl-4-benzoyl-imidazole (ABI) derivatives.

118 Auditory brainstem implants (ABIs) restore hearing by electrical stimulation of the c

119 ssociated favorably with common carotid IMT, ABI, and coronary artery calcification in men and with c

120 ning, statin use/non-use, ABI, and change in ABI, the PAD participants using statins had less annual

121 Decreases in ABI of more than 0.15 between Visit 1 and Visit 2 were s

122 A modest proportion of the variability in ABI is explained by genetic factors.

123 Genetic contributions to variation in ABI are largely unknown.

124 .90) and high (> or =1.40 or incompressible) ABI as compared with intermediate ABI in 5,330 older US

125 w (<0.90) and high (>1.40 or incompressible) ABI with LV mass by cardiac magnetic resonance imaging (

126 These factors were associated with increased ABI (P<0.05) in women only.

127 For all 3 methods, the index ABI was the lower of the ABIs calculated from the left a

128 is to determine if an ankle-brachial index (ABI) >or=1.40 is associated with reduced quality of life

129 men and women with an ankle brachial index (ABI) <0.90 and 212 with ABI 0.90 to 1.50.

130 measurement of the ankle-to-brachial index (ABI) and CASL.

131 studies (GWAS) of the ankle brachial index (ABI) and PAD (defined as an ABI < 0.90) have not been co

132 to those with a normal ankle-brachial index (ABI) and those with peripheral arterial disease (PAD).

133 on the use of resting ankle-brachial index (ABI) as a screening test for PAD or as a risk predictor

134 rdiovascular (CVD) had ankle brachial index (ABI) assessment of their bilateral dorsalis pedis/poster

135 nosis of LE-PAD is the ankle-brachial index (ABI) at rest and typically an ABI </= 0.90 is used to de

136 use of an alternative ankle-brachial index (ABI) calculation method improves mortality risk predicti

137 A low ankle brachial index (ABI) indicates atherosclerosis and an increased risk of

138 l artery disease as an ankle brachial index (ABI) lower than or equal to 0.90.

139 isease (CKD) with high ankle brachial index (ABI) measurement and to compare its strength with that o

140 he association of high ankle brachial index (ABI) measurements with left ventricular (LV) mass, and t

141 ligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascula

142 The ankle-brachial index (ABI) provides information on both atherosclerosis and ar

143 derline and low normal ankle-brachial index (ABI) values with functional decline over a 5-year follow

144 both a low and a high ankle-brachial index (ABI) with incident cardiovascular events in a multiethni

145 ts associated with the ankle-brachial index (ABI), a noninvasive measure of PAD, we conducted a meta-

146 d by low values of the ankle-brachial index (ABI), and future CVD risk has been demonstrated.

147 circulating PC levels, ankle brachial index (ABI), and walking impairment questionnaire (WIQ) and 36-

148 Ankle-brachial index (ABI), coronary artery calcification, and internal and co

149 ma media thickness and ankle-brachial index (ABI), for N = 549.

150 lcium (CAC) score, the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) levels

151 e ratio, also known as ankle-brachial index (ABI), in RA patients.

152 ods of calculating the ankle-brachial index (ABI).

153 y independently of the ankle brachial index (ABI).

154 tation better than the ankle-brachial index (ABI).

155 re and incident PAD by ankle brachial index (ABI).

156 shed by the use of the ankle-brachial index (ABI).

157 re (CAC score, >0), or ankle-brachial index (ABI, <0.90).

158 The ankle-brachial blood pressure index (ABI) is a widely utilized measure for detecting peripher

159 cts (YH) (n = 10; mean ankle-brachial index [ABI] 1.0 +/- 0.1, mean age 30 +/- 7 years); 2) periphera

160 membrane proteins with abortive infectivity (ABI) domains, elements first described in lactococci for

161 mechanisms of aggregation-based inhibition (ABI) and ABI-attenuation by additives, such as Triton X-

162 g the transcription factors ABA insensitive (ABI)4 and ABI5.

163 actors, including abscisic acid-insensitive (ABI)3 and ABI5, are known to control this developmental

164 ependent inactivation of the ABA-insensitive(ABI)-clade protein phosphatases(PP)2Cs, thereby permitti

165 al contribution of animal-borne instruments (ABI) into ocean observing systems (OOSs) and provide a f

166 pressible) ABI as compared with intermediate ABI in 5,330 older US men, among whom the mean serum pho

167 Compared with subjects with intermediate ABI, LV mass was higher with either low (2.70 g/m(2) hig

168 Intermediate ABIs served as the reference category.

169 irradiation (TBI) and abdominal irradiation (ABI) models to demonstrate a very limited, if any, role

170 Of those, 3350 with a low ABI (< or = 0.95) were entered into the trial, which was

171 ardiovascular disease, identified with a low ABI based on screening a general population, the adminis

172 Screening for a low ABI can identify an asymptomatic higher risk group poten

173 513 participants, 23% had CKD, 13% had a low ABI, and 3% had a high ABI.

174 g/dL (standard deviation, 0.4), 6% had a low ABI, and 5% had a high ABI.

175 are its strength with that of CKD with a low ABI.

176 tin C-based CKD was associated with both low ABI (relative risk [RR]: 2.0; 95% confidence interval [C

177 events in persons with a screen-detected low ABI but may have increased the risk for major bleeding e

178 ed with a 1.6-fold greater prevalence of low ABI (95% confidence interval (CI): 1.2, 2.1; P < 0.001)

179 stantially attenuated the association of low ABI with LV mass index (1.24 g/m(2) higher, 95% confiden

180 and to compare its strength with that of low ABI with LV mass.

181 er phosphorus levels are associated with low ABI and are also associated with high ABI in persons wit

182 rterial disease (PAD) patients (n = 12; mean ABI 0.6 +/- 0.1, mean age 71 +/- 9 years); and 3) age-ma

183 healthy control subjects (AHC) (n = 8; mean ABI 1.1 +/- 0.1, mean age 68 +/- 9 years).

184 The mean ABI was 1.1 (range, 0.4-1.4).

185 ean ancestry ( approximately 60% women, mean ABI 1.02 to 1.19), including 3409 participants with PAD

186 d should be further pursued in designing new ABIs.

187 ne ABI), 1.11 (low-normal ABI), 1.00 (normal ABI; referent), and 0.78 (high ABI); p for trend = 0.000

188 ne ABI), 1.14 (low-normal ABI), 1.00 (normal ABI; referent), and 1.43 (high ABI); p for trend = 0.000

189 oor survival, worse than those with a normal ABI or those with PAD.

190 loss compared with persons who have a normal ABI.

191 ), low normal ABI (1.00 to 1.09), and normal ABI (ABI 1.10 to 1.30).

192 tudy period was 88%, 70%, and 60% for normal ABI, PAD, and PCA, respectively.

193 .8 +/- 13.0 years, 59% male); 29% had normal ABI, 54% had PAD, and 17% had PCA.

194 ), borderline ABI (0.90 to 0.99), low normal ABI (1.00 to 1.09), and normal ABI (ABI 1.10 to 1.30).

195 A low normal ABI is associated with an increased incidence of mobilit

196 he associations of borderline and low normal ABI with functional decline are unknown.

197 3.07 (95% CI: 1.21 to 7.84); and low normal ABI, HR: 2.61 (95% CI: 1.08 to 6.32; p trend = 0.0018).

198 AD), 1.27 (borderline ABI), 1.11 (low-normal ABI), 1.00 (normal ABI; referent), and 0.78 (high ABI);

199 AD), 1.72 (borderline ABI), 1.14 (low-normal ABI), 1.00 (normal ABI; referent), and 1.43 (high ABI);

200 nd 1.3 (1.2 to 1.4) compared with the normal ABI and PAD groups, respectively.

201 iable-adjusted heritabilities for normalized ABI estimated using variance-components analysis were 0.

202 pair correlation coefficients for normalized ABI were 0.15 and 0.11, respectively, resulting in herit

203 Novel ABI-III compounds were designed and synthesized based on

204 okinetics, safety, and antiviral activity of ABI-H0731, an investigational inhibitor of the HBV core

205 Here, we investigate the molecular basis of ABI and ABI-attenuation through the lens of NMR and coup

206 a Assembler was modified for combinations of ABI 3730 and 454 FLX reads.

207 nd showed that it requires the SH3 domain of ABI-1.

208 signed (3:1) to receive single oral doses of ABI-H0731 (100, 300, 600, or 1000 mg) or matching placeb

209 acebo, or once-daily or twice-daily doses of ABI-H0731 800 mg or matching placebo for 7 days.

210 d with both the high and the low extremes of ABI in community-living older people.

211 were computed and assessed as a function of ABI and calf muscle group.

212 The heritability of ABI was estimated using variance-components methods in S

213 baseline required to plan the integration of ABI into global and regional OOS while integrating conse

214 eening method; the diagnostic performance of ABI testing in primary care populations, unselected popu

215 s associated with a 2-fold increased risk of ABI >1.4 (hazard ratio = 2.04, 95% CI: 1.02, 3.41).

216 was dose-related safety and tolerability of ABI-H0731 in healthy volunteers and in participants with

217 tomatic populations; the predictive value of ABI testing for major CVD outcomes in primary care or un

218 rieux] and amplification on QuantStudio 6 or ABI 7500 real-time PCR system [abbreviated CDC COV]) to

219 r incident PAD defined as either ABI <0.9 or ABI >1.4.

220 /Sra1/p140/PIR121, GEX-3/NAP1/HEM2/KETTE, or ABI-1/ABI, the three other components of the C. elegans

221 sequence data files produced by MegaBace or ABI sequencers as well as Staden SCF trace files and pla

222 ned by cCIMT but not by iCIMT, CAC score, or ABI.

223 (<0.70) and, in some cases, low (0.70 < or = ABI <0.90) Visit 2 ABIs were associated with significant

224 Continuous ABI and PAD (ABI </=0.9) phenotypes adjusted for age and sex were exa

225 , moderate PAD (ABI 0.50 to 0.69), mild PAD (ABI 0.70 to 0.89), borderline ABI (0.90 to 0.99), low no

226 llows: severe PAD (ABI <0.50), moderate PAD (ABI 0.50 to 0.69), mild PAD (ABI 0.70 to 0.89), borderli

227 Progressive PAD (ABI decline >0.15) was significantly and independently a

228 nts were categorized as follows: severe PAD (ABI <0.50), moderate PAD (ABI 0.50 to 0.69), mild PAD (A

229 or 4-vessel peripheral artery disease (PAD) (ABI of <=0.9).

230 in polymerization, similar to their parental ABI analogues.

231 In particular, ABI's sequencer (SOLiD system) poses a big computational

232 and safe approach for the treatment of post-ABI tremor in the largest series published at the time o

233 ries of eight consecutive patients with post-ABI tremor were treated with DBS of the ventro-oralis po

234 idopsis clade A type 2C phosphatases (PP2Cs) ABI/HAB group and AHG3, thus triggering their degradatio

235 I-LO"), 2) with the highest ankle pressure ("ABI-HI"), and 3) with the mean of the ankle pressures ("

236 nd 3) with the mean of the ankle pressures ("ABI-MN").

237 aryl group and the benzoyl group of previous ABI structures and were named as reverse ABI (RABI) anal

238 lengths generated in Applied Biosystems(R) (ABI) either manually or automatically by providing panel

239 ort) were randomly assigned (5:1) to receive ABI-H0731 (100, 200, 300, or 400 mg) or matching placebo

240 grade among the 74 participants who received ABI-H0731 were headache (11 [15%]), influenza-like illne

241 None of the previously reported ABI and PAD associations in whites generalized to Hispan

242 synthesized based on our previously reported ABI-I and ABI-II analogues.

243 The review focused on resting ABI as the sole screening method; the diagnostic perform

244 ous ABI structures and were named as reverse ABI (RABI) analogues.

245 However, in mice treated with DEX and Scl-ABI, a significant increase in trabecular bone at the fe

246 CAC score, ABI, and FH were independent predictors of ASCVD events

247 CAC score, ABI, and FH were independent predictors of ASCVD events.

248 the colchicine binding site based on SMART, ABI, and PAT templates, we have designed, synthesized, a

249 Specifically, ABI have the potential to fill gaps in marginal seas, up

250 stic significance of declining versus stable ABI has not been studied.

251 -Agilent] and the 7500 real-time PCR system [ABI Life Technologies]).

252 The ABI is used to diagnose peripheral arterial disease (PAD

253 The ABI was calculated at baseline in 1,413 study participan

254 The ABI was categorized as low (<0.90), low-normal (0.90 to

255 The ABI/INFORM, Embase, JSTOR, PubMed, and WHO Index Medicus

256 Adding the ABI to the FRS probably has limited value for predicting

257 allelic discrimination Taqman assay and the ABI 7900HT Sequence Detection System (v2.1) was used to

258 We performed a GWAS of PAD and the ABI in 7,589 participants aged >45 years from the Hispan

259 nd newer biomarker CVD risk factors, and the ABI significantly improved risk discrimination.

260 ustment for traditional risk factors and the ABI.

261 ntitis based on AL and PAD determined by the ABI (odds ratio = 8.18).

262 zed fingerprinting profiles generated by the ABI Genetic Analyzers.

263 persons with PAD beyond that provided by the ABI.

264 nd on the ankle pressure used to compute the ABI.

265 genome-wide significant associations for the ABI in COMMD10 in Puerto Ricans, and at SYBU in the Cari

266 MD10 gene had a replication p = 0.02 for the ABI in Multi-Ethnic Study of Atherosclerosis (MESA) Afri

267 sized fragment information directly from the ABI raw trace files, or from data files exported from Ge

268 There were no significant differences in the ABI, WIQ distance and speed scores, claudication onset t

269 d measures of subclinical CVD, including the ABI.

270 ress the cost effectiveness of measuring the ABI in targeted population groups.

271 e men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization.

272 All sites performed the ABI using a Doppler device and a standardized technique.

273 e excretory cell canals, suggesting that the ABI-1/MIG-10 interaction is relevant in vivo.

274 To address the hypothesis that the ABI-clade PP2Cs regulate the bZIPs directly, in addition

275 Traditionally, the ABI is calculated with the higher of the dorsalis pedis

276 nucleotide polymorphism rs12979860 using the ABI TaqMan allelic discrimination kit.

277 s1127354 and rs7270101 were tested using the ABI TaqMan kit.

278 trol samples when RNA was isolated using the ABI Tempus method, but not using the PAXgene method (p <

279 itude of the NRI was probably small when the ABI was added to the FRS to predict CAD or CVD events.

280 ing for PAD and CVD risk assessment with the ABI in adults.

281 methods, the index ABI was the lower of the ABIs calculated from the left and right legs.

282 ratios (HRs) for mobility loss according to ABI category were as follows: severe PAD, HR: 4.16 (95%

283 l-PAD group (ABI <0.90) with the traditional ABI method.

284 ty who are currently missed with traditional ABI methods.

285 better understand the mechanisms underlying ABIs, we tested if electrical stimulation of the rat DCN

286 evious year functioning, statin use/non-use, ABI, and change in ABI, the PAD participants using stati

287 e magnitudes of association were found using ABI-LO.

288 al atherosclerosis and CVD risk factors when ABI-HI was used, except when risk estimates for PAD were

289 r in women and 2.74 times higher in men when ABI-LO was used.

290 Our analyses identify potential areas where ABI could complement OOS.

291 nkle brachial index (ABI) <0.90 and 212 with ABI 0.90 to 1.50.

292 nificant association on chromosome 9p21 with ABI.

293 sed arsenic methylation were associated with ABI >1.4 but not with ABI <0.9.

294 r = 0.05) were significantly associated with ABI change independently of baseline ABI and cardiovascu

295 coronary artery disease are associated with ABI.

296 coronary artery disease were associated with ABI: DAB21P (rs13290547, P=3.6x10(-5)), CYBA (rs3794624,

297 ar CDKN2B had the strongest association with ABI (beta=-0.006, P=2.46x10(-8)).

298 e used to test each SNP for association with ABI and PAD using additive genetic models.

299 sed to evaluate the associations of CKD with ABI categories.

300 examination: 2000-2002), in comparison with ABI-HI, the relative prevalence of PAD was 3.95 times hi

301 zero, except for hepcidin and ferritin with ABI at rest [-0.27 (SE 0.34) and -0.22 (SE 0.35), respec

302 n were associated with ABI >1.4 but not with ABI <0.9.